Cochran Firm, D.C. Investigating AndroGel, Axiron And Other Potential Testosterone Replacement Therapy Lawsuit Cases
Injury and product liability law firm accepting claims from individuals who suffered serious health problems while on low-T testosterone replacement therapy.
March 4, 2014 (Newswire.com) - Recent medical studies have linked low-T testosterone therapy products like AndroGel and Axiron to serious cardiovascular health problems such as heart attack, stroke, and even death. On Jan. 31, 2014, the Food and Drug Administration (FDA) issued a safety announcement stating that it is investigating the health and safety risk of low testosterone products. In response to the FDA's announcement and communications to our office by individuals injured by low-T drugs, The Cochran Firm, D.C. today announces it is actively investigating injuries related to low testosterone products like AndroGel, Axiron, Fortesta, and Testim and is accepting cases from individuals who suffered health problems while taking low-T drugs.
"Recent revelations about low-T testosterone products in the Journal of the American Medical Association and the PLOS One journal indicate that there are potentially serious health risks with these products that were not disclosed to the public," David Haynes, managing attorney of The Cochran Firm, D.C., said. "We are actively and aggressively investigating legal claims related to low-T testosterone therapy including popular products like AndroGel, Axiron, Fortesta, and Testim."
Individuals who suffered cardiovascular health problems like heart attacks and strokes have filed federal lawsuits against AbbVie Inc. and Abbot Laboratories, the makers and distributors of AngroGel. The testosterone therapy lawsuits allege that AndroGel was misrepresented as a safe and effective treatment for hypogonadism or "low testosterone." The case names and numbers for these low-T testosterone lawsuits are Marino v. AbbVie Inc., 14-cv-00777; Gallagher v. AbbVie Inc., 14-cv-00776; and Myers v. AbbVie Inc., 14- cv-00780; Aurecchia v. AbbVie Inc., 14-cv-00772; and Benn v. AbbVie, 14-cv-00774 U.S. District Court, Northern District of Illinois.
Recent medical studies indicated that there may be serious health risks with low-T testosterone replacement therapy products. A 2010 New England Journal of Medicine study into low-T products was halted due to a higher incidence of negative cardiovascular events. A 2013 study in the Journal of the American Medical Association suggests that testosterone replacement therapy increased the risk of heart attack, stroke, and death by approximately 30%. A 2014 medical study in PLOS ONE (the Public Library of Science's open access peer-reviewed scientific journal) indicates that testosterone replacement therapy products doubled the risk of heart attack in men older than 65 years old and men younger than 65 with a prior heart condition.
In reaction to the troubling findings by these medical studies, the Food and Drug Administration (FDA) issued a safety announcement on Jan. 31, 2014, about low-T testosterone gel, cream, roll-on, and other topical products. The FDA recommended that patients should not stop taking prescribed testosterone products without first discussing the low-T testosterone product with their doctor.
The product liability and injury attorneys of The Cochran Firm, D.C. invite members of the public who have experience adverse health effects while taking low-T testosterone replacement therapy products to visit http://www.cochranfirmdc.com/ or call 202-682-5800. Individuals who suffered serious health problems such as heart attack, stroke, and thrombolytic events while taking low-T testosterone products may be eligible for compensation. Because time limits apply to pursuing legal claims, it is recommended that individuals who took low-T products should contact The Cochran Firm, D.C. as soon as convenient.
Categories: Pharmaceuticals and Biotech